Journal
Blood Advances
Publication Date
6-13-2023
Volume
7
Issue
11
First Page
2287
Last Page
2296
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2022009225
Rights and Permissions
Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 Jun 13;7(11):2287-2296. doi: 10.1182/bloodadvances.2022009225. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Epperla, Narendranath; Malecek, Mary-Kate; Kahl, Brad S; Bartlett, Nancy L; and et al., "Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma." Blood Advances. 7, 11. 2287 - 2296. (2023).
https://digitalcommons.wustl.edu/oa_4/2195
Additional Links
Supplemental material is available for this article at publisher site.
